Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Captrust Financial Advisors

Captrust Financial Advisors raised its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 2,567.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 215,322 shares of the company's stock after purchasing an additional 207,250 shares during the quarter. Captrust Financial Advisors owned 0.77% of Castle Biosciences worth $5,738,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of CSTL. Covestor Ltd purchased a new stake in shares of Castle Biosciences during the fourth quarter worth $25,000. R Squared Ltd purchased a new stake in shares of Castle Biosciences during the fourth quarter worth $42,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Castle Biosciences during the fourth quarter worth $128,000. China Universal Asset Management Co. Ltd. increased its position in shares of Castle Biosciences by 11.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company's stock worth $158,000 after acquiring an additional 604 shares during the period. Finally, Oak Harvest Investment Services purchased a new stake in shares of Castle Biosciences during the fourth quarter worth $206,000. Hedge funds and other institutional investors own 92.60% of the company's stock.

Insider Transactions at Castle Biosciences

In other news, insider Derek J. Maetzold sold 22,639 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $20.12, for a total transaction of $455,496.68. Following the completion of the sale, the insider now owns 80,465 shares in the company, valued at approximately $1,618,955.80. This represents a 21.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders sold 27,454 shares of company stock worth $553,030. Company insiders own 7.20% of the company's stock.

Analyst Upgrades and Downgrades

CSTL has been the topic of several recent analyst reports. Robert W. Baird increased their target price on Castle Biosciences from $36.00 to $37.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Lake Street Capital dropped their target price on Castle Biosciences from $40.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Canaccord Genuity Group dropped their target price on Castle Biosciences from $42.00 to $37.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Finally, Guggenheim set a $30.00 target price on Castle Biosciences and gave the company a "buy" rating in a report on Friday, March 28th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $37.50.

Castle Biosciences Stock Performance

NASDAQ CSTL traded down $0.50 during trading hours on Wednesday, hitting $16.53. The company had a trading volume of 165,935 shares, compared to its average volume of 402,519. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. Castle Biosciences, Inc. has a 1-year low of $15.70 and a 1-year high of $35.84. The company has a market cap of $477.25 million, a PE ratio of 82.65 and a beta of 1.19. The business has a 50 day moving average of $19.67 and a 200-day moving average of $25.41.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.12). Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. The business had revenue of $87.99 million for the quarter, compared to analyst estimates of $80.40 million. As a group, equities research analysts expect that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.